Seqster, Boehringer Ingelheim, Partner up on Patient Engagement

Published on: August 4, 2022

Multi-year deal aims to put patients at the center of their clinical data

Seqster, a health-tech company, announced a three-year partnership with Boehringer Ingelheim to connect the patients to all of their health data. For patients, the Digital Front Door unlocks interoperability, patient access, data sharing, simplifies the informed consent process, boosts participant engagement leading to retention, alleviates caregiver burden, all while ensuring patient health data security and privacy. The Digital Front Door is powered by the Seqster Operating System (SeqsterOS). For researchers, real-time real-world data (RWD) accelerates real-world evidence (RWE), outcomes research, and drug development.

According to Seqster, its operating system standardizes, harmonizes and visualizes retrospective and prospective health data, offering a comprehensive, longitudinal health record that empowers and engages patients, while providing consented, de-identified data for studies in real-time.

"The significance of our joint initiative with Boehringer Ingelheim cannot be understated. There is a natural alignment between both organizations as we seek to accelerate data-driven discoveries and impact patient lives at scale," says Ardy Arianpour, CEO and co-founder of Seqster, who was previously a guest on The Pharmaceutical Commerce Podcast. "Empowering patients with access to the Digital Front Door allows them to connect and engage with their data, leading to improved study retention, as well as a willingness to consent to future studies."